Article Text

PDF

Extended report
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
  1. P J Mease1,
  2. R Fleischmann2,
  3. A A Deodhar3,
  4. J Wollenhaupt4,
  5. M Khraishi5,
  6. D Kielar6,
  7. F Woltering7,
  8. C Stach7,
  9. B Hoepken7,
  10. T Arledge8,
  11. D van der Heijde9
  1. 1Swedish Medical Center and University of Washington, Seattle, Washington, USA
  2. 2University of Texas SW Medical Center, Dallas, Texas, USA
  3. 3Div Arthritis/Rheumatic Diseases (OPO9), Oregon Health & Science University, Portland, Oregon, USA
  4. 4Klinik für Rheumatologie und klinische Immunologie, Schoen Klinik, Hamburg, Germany
  5. 5Memorial University of Newfoundland, Nexus Clinical Research, St. John's, Newfoundland and Labrador, Canada
  6. 6UCB Pharma, Brussels, Belgium
  7. 7UCB Pharma, Monheim am Rhein, Germany
  8. 8UCB Pharma, Raleigh, North Carolina, USA
  9. 9Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
  1. Correspondence to Professor Philip J Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA, 98122, USA; pmease{at}philipmease.com

Abstract

Objectives To evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in RAPID-PsA (NCT01087788), an ongoing Phase 3 trial in patients with psoriatic arthritis (PsA).

Methods Patients were randomised 1:1:1 to placebo, 200 mg CZP every 2 weeks (Q2W) or 400 mg CZP every 4 weeks (Q4W). Patients could have had exposure to one previous tumour necrosis factor (TNF) inhibitor therapy. Primary endpoints were American College of Rheumatology 20% (ACR20) response at week 12 and modified Total Sharp Score change from baseline at week 24. Secondary endpoints included; Psoriatic Arthritis Response Criteria (PsARC) score, Health Assessment Questionnaire Disability Index (HAQ-DI), Psoriasis Area and Severity Index, Leeds Enthesitis Index, Leeds Dactylitis Index, and Modified Nail Psoriasis Severity Index.

Results Of 409 patients randomised, 368 completed 24 weeks of treatment. ACR20 response was significantly greater in CZP 200 mg Q2W and 400 mg Q4W-treated patients than placebo (58.0% and 51.9% vs 24.3% (p<0.001)) at week 12, with improvements observed by week 1. There was a statistically significant improvement in physical function from baseline, measured by HAQ-DI in CZP patients compared with placebo (−0.50 vs −0.19, p<0.001) and more patients treated with CZP 200 mg Q2W and CZP 400 mg achieved an improvement in PsARC at week 24 than placebo (78.3% and 77.0% vs 33.1% (p<0.001)). Sustained improvements were observed in psoriatic skin involvement, enthesitis, dactylitis and nail disease. Higher ACR20 response with CZP was independent of prior TNF inhibitor exposure. No new safety signals were observed.

Conclusions Rapid improvements in the signs and symptoms of PsA, including joints, skin, enthesitis, dactylitis and nail disease were observed across both CZP dosing regimens.

  • Anti-TNF
  • Treatment
  • Psoriatic Arthritis

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

View Full Text

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles